Post hoc analyses of the ORION-9, ORION-10, and ORION-11 trials further showed that inclisiran significantly decreased PCSK9 levels and other atherogenic lipids in patients with diabetes or obesity [135,136]. This evidence concerns the gene PCSK9 and diabetes mellitus.